Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 201–300 of 666
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 50
Psarou, A., Cooper, H., & Wilding, J. P. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0490-5 · Cited by 29
Christiansen, J. S., Niskanen, L., Rasmussen, S., Johansen, T., & Fulcher, G. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12355 · Cited by 26
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 26
“(meglitinide and sulfonylurea (SU)) Options to continue, reduce, or stop the sulfonylurea [7, 8, 93]”
BackgroundBarag, S. (2011) · PubMed · Cited by 29
The 2012 SEMDSA Guideline for the Management of type 2 Diabetes
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872277 · Cited by 39
Hompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0117 · Cited by 25
“0%.(7,8) The contribution that PPG makes to A1C becomes greater as the A1C approaches target values,(1,3) underscoring the need for effective prandial insulin treatment.”
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Harris, S. B., Yale, J., Berard, L., Stewart, J. A., Abbaszadeh, B., Webster-Bogaert, S., & Gerstein, H. C. (2013) · Diabetes Care · doi:10.2337/dc13-1636 · Cited by 28
Lajara, R., Fetchick, D. A., Morris, T. L., & NIKKEL, C. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0138-7 · Cited by 24
“gov identifier, NCT00184600), most patients (82%) required insulin intensification to include mealtime bolus insulin by 3 years to achieve glycemic targets [4].”
GLP-1 analogues and insulin: sound the wedding bells?
Nauck, M. A., & Meier, J. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.30 · Cited by 26
Pharmacologic Treatment of Type 2 Diabetes
Tran, L. T., Zielinski, A., Roach, A., Jende, J. A., Householder, A., Cole, E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S., et al. (2015) · The Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 33
“Numerous titration algorithms have been published, including both clinic- and patient-driven adjustments.(89,103,108,109,113-126) Use of algorithms led to improved glycemic control and low risk of severe hypoglycemia, provided the morning fasting blood glucose target was not <100 mg/dL.”
BackgroundMethodLajara, R., Davidson, J. A., NIKKEL, C. C., & Morris, T. L. (2016) · Endocrine Practice · doi:10.4158/ep151182.or · Cited by 25
Parthsarathy, V., Hogg, C., Flatt, P. R., & O'Harte, F. P. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13068 · Cited by 30
“FIGURE 1 Chronic effect of twice-daily administration of exendin-4(1-39), apelin-13 amide or (pGlu)apelin-13 amide (each at 25 nmol/kg body weight) on A, body weight; B, percent body weight change; C, cumulative energy intake; D, non-fasting blood glucose and E, plasma insulin during 28-day treatment.”
BackgroundMethodInfluentialPredictors of responders to insulin therapy at 1 year among adults with type 2 diabetes
Owen, V., Seetho, I. W., & IDRIS, I. R. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01239.x · Cited by 26
“Our study also showed that patients receiving a premixed regime were most probably to exhibit the most weight gain compared to those who received a basal-bolus insulin regimen or a basal insulin alone, consistent with findings from the recent 4T study at 3 years follow-up [14].”
ResultDivergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis
Bell, D. S. H., Patil, H., & O’Keefe, J. H. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0671 · Cited by 27
Lévy, J., Davies, M. J., & Holman, R. R. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.01.022 · Cited by 27
Self-citationRecomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, F. J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Atención Primaria · doi:10.1016/j.aprim.2010.07.012 · Cited by 30
Heise, T., Nosek, L., Klein, O., Coester, H. V., Svendsen, A. L., & Haahr, H. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12463 · Cited by 23
“The shoulder effect observed with BIAsp30, might, at least in part, be the reason for the higher hypoglycaemia rates observed with BIAsp30 when compared with basal insulin analogues [4,18].”
ResultLeinung, M. C., Thompson, S., Luo, M., Leykina, L., & Nardacci, E. (2012) · Endocrine Practice · doi:10.4158/ep12104.or · Cited by 23
Diabetes mellitus: Exploring the challenges in the drug development process
Patnaik, A., & Vaz, J. A. (2012) · Perspectives in Clinical Research · doi:10.4103/2229-3485.100660 · Cited by 26
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Schinner, S. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79453-1 · Cited by 24
Hunt, B., Mocarski, M., Valentine, W. J., & Langer, J. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1301943 · Cited by 24
Insulin initiation and intensification in patients with T2DM for the primary care physician
Unger, J. R. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s14653 · Cited by 22
“Most OADs lose effectiveness over time, requiring frequent monitoring of A1C levels and adjustment of the treatment regimen to achieve or maintain adequate glycemic control.(30) As β-cell function declines further, the use of mealtime insulin replacement therapy must be considered to minimize postprandial hyperglycemi…”
Personalizing guidelines for diabetes management: twilight or dawn of the expert?
Paschou, S. Α., & Leslie, R. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-161 · Cited by 23
Acute consequences of hypoglycaemia in diabetic patients
Halimi, S. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70471-7 · Cited by 28
SUTTON, D. R., Higdon, C., NIKKEL, C. C., & Hilsinger, K. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0703-3 · Cited by 21
“showed that 82% of patients on basal therapy required mealtime insulin boluses within 3 years to reach targets [26].”
BackgroundDemir, T., Turan, S., Ünlühızarcı, K., Topaloğlu, O., Tükek, T., & Yavuz, D. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.616514 · Cited by 22
Elizarova, S. V., Galstyan, G. R., & Wolffenbuttel, B. H. R. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12096 · Cited by 23
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Moghissi, E. S., & King, A. B. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.002 · Cited by 22
Dieuzeide, G., Chuang, L., Almaghamsi, A. M., Zilov, A. V., Chen, J.-W., & Lavalle-Gonzalez, F. J. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.07.005 · Cited by 21
Downie, M. R., Kilov, G., & Wong, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0199-2 · Cited by 21
“In the 3-year follow-up of the ‘4T’ trial [NCT00184600], similar median HbA1c levels were achieved, with a lower hypoglycemia rate seen in the basal insulin detemir group [17].”
BackgroundAndo, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Malek, R., Ajili, F., Assaad-Khalil, S. H., Shinde, A., Chen, J. W., & van den Berg, E. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.11.002 · Cited by 20
Mikkelsen, K. H., Klausmann, Hramiak, Qvist, & Guo, X. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s41929 · Cited by 23
“A recent study has shown that a number of different insulin regimens are effective in enabling blood glucose levels to reach target values.(26,27) Some regimens may require multiple insulin injections each day, and in some instances may require adjustments to the amount of insulin that needs to be injected to maintain…”
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
Hunt, B., Mocarski, M., Valentine, W. J., & Langer, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0251-x · Cited by 21
Woo, V. C., Berard, L., BAJAJ, H. S., Ékoé, J.-M., & Senior, P. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.01.009 · Cited by 21
Hanefeld, M., Fleischmann, H., Schiffhorst, G., & Bramlage, P. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0246 · Cited by 20
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.002 · Cited by 23
“[10] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.”
BackgroundRecomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Revista Clínica Española · doi:10.1016/j.rce.2010.11.006 · Cited by 22
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 20
Li, C., Ford, E. S., Zhao, G., Tsai, J. H., Balluz, L. S., & Giles, W. H. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.11.005 · Cited by 22
Obesity and type 2 diabetes: can we find a compromised treatment solution?
Galstyan, G. R., Shestakova, E. A., & Sklyanik, I. A. (2017) · Diabetes Mellitus · doi:10.14341/dm8726 · Cited by 26
“В исследовании 4-Т оценивались гликемический контроль, частота гипогликемий и изменение веса на фоне 3 различных режимов инсулинотерапии у 708 пациентов, не достигших контроля на терапии метформином и препаратами сульфонилмочевины (ПСМ) [21].”
Jones, A. G., Besser, R. E. J., Shields, B. M., McDonald, T. J., Hope, S. V., Knight, B., & Hattersley, A. T. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-6 · Cited by 20
“However in Type 2 diabetes where endogenous insulin secretion is preserved, excellent glycaemic control can be achieved using basal (intermediate or long acting) insulin without rapid or short acting prandial insulin [22,23].”
BackgroundCost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
Oyagüez, I., Peralta, F. G., Artola, S., Carrasco-Sánchez, F. J., Carretero‐Gómez, J., Soidán, F. J. G., Gómez‐Huelgas, R., Merino-Torres, J. F., & Pérez, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01064-4 · Cited by 25
“The incidence of hypoglycaemia is higher among insulin-treated patients with T2DM [10, 11], primarily those with complex insulin regimens following the use of basal insulin, who also required personalized treatment adjustments with several types of insulin.”
BackgroundShaefer, C. F., Reid, T., DAILEY, G. E., Mabrey, M., Vlajnic, A., Stuhr, A., Stewart, J. A., & Zhou, R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2824 · Cited by 19
Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
Goldenberg, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.852078 · Cited by 18
Levit, S., Toledano, Y., & Wainstein, J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02513.x · Cited by 19
Simplification of complex insulin therapy: a story of dogma and therapeutic resignation
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108958 · Cited by 22
Moawd, S. A. A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1633448 · Cited by 20
“The reason for the association between diabetes stress and sleep is that poor sleep could lead to insulin resistance and be the cause of poor glycemic control [20], thus diabetes stress.”
BackgroundAdvances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L., Smits, M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 22
Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics
Perfetti, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0250 · Cited by 18
“The American Diabetes Association/European Association for the Study of Diabetes consensus statement proposes the add-on of short-acting insulin at mealtimes to correct postprandial hyperglycemia,(1) and studies have demonstrated the efficacy of this approach.(9,15) This strategy recommends that in patients on basal i…”
BackgroundMader, J. K., Lilly, L. C., Aberer, F., Poettler, T., Johns, D., TRAUTMANN, M. E., WARNER, J. L., & Pieber, T. R. (2018) · Diabetic Medicine · doi:10.1111/dme.13708 · Cited by 18
Clements, J. N., Albanese, N. P., D’Souza, J. J., Misher, A., Reece, S. W., Trujillo, J. M., & Whitley, H. P. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1512 · Cited by 18
“Some evidence indicates that basal insulin is associated with less weight gain compared to biphasic or prandial insulin.(59) Therefore, if insulin is needed for glucose man-”
BackgroundInternational Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21
Khoo, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00079-x · Cited by 17
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 30
Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2
Hanefeld, M., Ganz, X., & Nolte, C. (2014) · Herz · doi:10.1007/s00059-014-4086-1 · Cited by 18
Linetzky, B., Curtis, B. H., Frechtel, G. D., Montenegro, R. M., Escalante-Pulido, M., Stempa, O., de Lana, J. M., & Gagliardino, J. J. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0157-1 · Cited by 16
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
“7%).(20) The longacting insulin analogues detemir and glargine 100 U/mL have been associated with a lower risk for hypoglycemia compared with that with NPH insulin.”
BackgroundGlycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment
Fonseca, V. A., & Haggar, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.17 · Cited by 16
Lee, B., Kim, J. H., Ko, S., Hur, K.-Y., Kim, N. H., Rhee, S. Y., Kim, H. J., Moon, M. K., Park, S.-O., & Choi, K. M. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.367 · Cited by 20
Optimal Insulin Treatment in Type 2 Diabetes
Roden, M. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908706 · Cited by 19
Yu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.001 · Cited by 15
Eliasson, B., Ekström, N., Wirta, S. B., Odén, A., Fard, M. P., & Svensson, A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0068-9 · Cited by 16
“However, at 3 years of follow-up the insulin regimens were equally effective in controlling HbA1c, but the lower rate of hypoglycemia in the basal insulin group remained [21].”
BackgroundAchieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Self-citationLiebl, A., Jones, S., Goday, A., Benroubi, M., Castell, C., Haupt, A., Nicolay, C., & Smith, H. T. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0009-4 · Cited by 16
“therapy regimen, highlighting the need for further adjustment of therapy [15].”
BackgroundHypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices
Bloomgarden, Z. T., & EINHORN, D. F. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00066 · Cited by 15
“The use of basal insulin detemir as primary treatment leads to two and threefold lower overall likelihood of hypoglycemia than multiple dose biphasic or prandial insulin (Holman et al., 2007, 2009).”
BackgroundOdawara, M., Kadowaki, T., & Naito, Y. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-20 · Cited by 15
“It has been demonstrated that first insulinization with basal insulin is effective and safe with reduced AEs including hypoglycemia, in clinical trial [38], as well as real-world setting [15].”
BackgroundSodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
Li, J., Fagbote, C. O., Zhuo, M., Hawley, C. E., & Paik, J. M. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz100 · Cited by 15
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01414-3 · Cited by 17
“When insulin therapy is required to treat T2D, basal insulin (BI) is the preferred initial approach, because it allows similar glycemic improvement as compared with more intensive regimens, but with lower hypoglycemia risk [1].”
BackgroundMiao, R., Wei, W., Başer, O., & Xie, L. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s49287 · Cited by 15
“Compared with basal insulin alone, PMX regimens have been associated with a greater reduction in A1C levels, but place significant restrictions on the timing of meals, and tend to cause more hypoglycemia and weight gain.(11,12) When patients with T2DM require intensification of insulin therapy, choosing the most appro…”
Inpatient Treatment of Type 2 Diabetes
Breuer, T. G. K., & Meier, J. J. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0466 · Cited by 18
“For long-term treatment, the oncedaily administration of a long-acting insulin analogue seems to lead to fewer hypoglycemic episodes than the administration of short-acting insulin three times a day, while yielding comparable HbA1c values (21, 22).”
BackgroundEffects of a Patient Education Support Program on Pramlintide Adherence
Lorenzi, G. M., LaRue, S. M., & Collins, S. E. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.17 · Cited by 17
Lundby‐Christensen, L., Vaag, A. A., Tarnow, L., Almdal, T., Lund, S. S., Wetterslev, J., Gluud, C. N., Boesgaard, T. W., Wiinberg, N., Perrild, H., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008377 · Cited by 16
“with T2D during 3 years.(6) 39 The initial treatment arms included basal insulin detemir, premixed insulin aspart as”
MethodResultFrias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Rys, P., Wojciechowski, P., Siejka, S. J., Małecki, P., Hak, Ł., & Malecki, M. T. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12337 · Cited by 14
The diabetes pandemic: is structured education the solution or an unnecessary expense?
Deakin, T. (2011) · Practical Diabetes · doi:10.1002/pdi.1635 · Cited by 17
Management of patients with type 2 diabetes
Nelson, S. E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.611797 · Cited by 16
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
Abdul-Ghani, M. A., Migahid, O., Megahed, A., DeFronzo, R. A., Zirie, M. A., & Jayyousi, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3423 · Cited by 14
Khunti, K., Vora, J. P., & Davies, M. J. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2013.11.010 · Cited by 13
“Some patients are able to achieve and maintain glycaemic control through changes in lifestyle and the use of oral anti-diabetic drugs (OADs) but treatment intensification with insulin will eventually be required by many patients with type 2 diabetes [6].”
BackgroundInfluentialSelf-citationWeight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 18
Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes
Blevins, T. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2313 · Cited by 17
Cohen, O., Filetti, S., Castañeda, J., Maranghi, M., & Glandt, M. (2016) · Diabetes Care · doi:10.2337/dcs15-3029 · Cited by 18
When Insulin Therapy Fails: The Impact of SGLT2 Inhibitors in Patients With Type 2 Diabetes
Harris, S. B., Mequanint, S., Miller, K., Reichert, S. M., & Spaic, T. (2017) · Diabetes Care · doi:10.2337/dc17-0744 · Cited by 14
Inagaki, N., Harashima, S., Kaku, K., Kondo, K., Maruyama, N., Otsuka, M., Kawaguchi, Y., & Iijima, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13152 · Cited by 15
“Prior evidence has demonstrated that insulin doses typically need to be increased to maintain glycaemic control as the duration of treatment increases.(31,32) In this study, the combination of canagliflozin and insulin allowed for long-term glycaemic control without increases in insulin doses.”
BackgroundRSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 16
Comparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
Self-citationDonnelly, R., Carr, S. V., & Harper, R. (2015) · Practical Diabetes · doi:10.1002/pdi.1966 · Cited by 14
Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring
Monnier, L., Azrak, A. E., Lessan, N. G., Rochd, D., Colette, C., & Bonnet, F. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.09.002 · Cited by 12
Durak, A. T., Bitirim, C. V., & Turan, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06974-2 · Cited by 12
Liu, S.-C., Lee, C.-C., Chuang, S., Sun, F., & Zeng, Y.-H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.001 · Cited by 15
Wang, H., Zhou, Y., Wang, Y., Cai, T., Hu, Y., Jing, T., Ding, B., Su, X., Li, H., & Ma, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.791439 · Cited by 13
Darbyshire, J. L., & Price, H. C. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001252 · Cited by 13
Self-citationZhang, Y., Xie, Y., Meng, D.-D., Zhang, H., Chen, H., & Liu, E. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-37 · Cited by 14
Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes
Lilly, L. C., Mader, J. K., & WARNER, J. L. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818807223 · Cited by 13
“Over time, many adults with T2DM require basal bolus insulin therapy to reach glycemic targets.(3) However, the majority of adults on insulin in the United States are not in good control.”
BackgroundJude, E. B., Trescolí, C., Emral, R., Ali, A., LUBWAMA, R. N., PALMER, K. D., Shaunik, A., Nanda, N., Raskin, P., & Peralta, F. G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14298 · Cited by 13
AlRuthia, Y. S., Bahari, O. H., Alghnam, S. A., Alrumaih, A. M., Asiri, H. M., Alshammari, M., Alhowimel, M., & Alabdulkarim, H. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.852721 · Cited by 12
“, NPH/regular (70/30), protamine/lispro (50/50), and protamine/aspart (70/30)] to make its onset of action faster (9).”
BackgroundPeralta, F. G., Barrera, F., Félix-Redondo, F. J., Fraile-Gómez, J., & on behalf of the Extreme Rescue Study Group (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.03000.x · Cited by 12
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.